Genetic Technologies Limited (GENE) Stock

Genetic Technologies Limited, a molecular diagnostics company, specializes in providing predictive testing and assessment tools aimed at enhancing women's health management in Australia and the United States. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians, gynecologists, and breast cancer risk assessment specialists, including breast surgeons.

Genetic Technologies offers a suite of cancer risk assessment tests under the GeneType brand, which includes GeneType for Colorectal Cancer and GeneType for Breast Cancer. The company is also actively developing risk assessment tests for a broad range of diseases, such as cardiovascular conditions, type 2 diabetes, prostate cancer, and melanoma. Besides its focus on human health, the company provides genetic testing services that span medical, animal, forensic, and plant testing domains.

Genetic Technologies Limited engages in extensive research and collaboration efforts, partnering with prestigious institutions such as the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York, Cambridge University, the Ohio State University, and Shivom. Founded in 1987, the company is headquartered in Fitzroy, Australia. Through its innovative testing solutions and collaborative research, Genetic Technologies Limited is at the forefront of advancing precision medicine and predictive health diagnostics.